Preloader Close
I B R A H I M R S E A R C H

We explore synthetic lethal interactions in rare and under-researched cancers using FDA-approved therapies. By targeting oxidative DNA damage, replication-coupled lesions, and checkpoint dysfunction, we aim to rapidly repurpose existing compounds for new clinical indications. This approach shortens the path from discovery to patient application.

Precision Discovery. On Track to Cure.